A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1067 participants.
Also called NCT01493557
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 1,067 participants
- Sponsor
- Registry
-
NCT01493557
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT01493557. Randomized; no masking; primary purpose prevention. Start 2011-12 (registry gives no type); primary completion 2014-07 (actual). Results posted on 2015-10-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- pantoprazole
- Intervention (Drug)
- Pradaxa (dabigatran etexilate)
- Intervention (Drug)
- Pradaxa, within 30 minutes after a meal
- Intervention (Drug)
- Pradaxa (dabigatran etexilate)
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct01493557- Content hash
776f2598417cbc7a122302c618a0cacf500d86e5ee0db5950af9761469a15dc3